Hudson Bay Capital Management
NKTR icon

Hudson Bay Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Hudson Bay Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,333
Closed -$270K – 1395
2022
Q1 		$270K Buy
3,333
+1,326
+66% +$196K ﹤0.01% 901
2021
Q4 		$407K Buy
+2,007
New +$435K ﹤0.01% 869

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's NKTR Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 10,332 shares — an estimated $743K sold.

Hudson Bay Capital Management first reported a position in NKTR in Q2 2018 and held it in 16 quarters. The position peaked at $6.13M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 10,332 Nektar Therapeutics shares in Q2 2026, an estimated $743K.
  • Hudson Bay Capital Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 16 quarters.
  • Hudson Bay Capital Management's Nektar Therapeutics position peaked at $6.13M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.